[1] 靳赢, 王琳源, 林晓萍. 实验性牙周炎中调节性T细胞的检测及免疫状态 [J]. 上海口腔医学, 2013, 22(5): 487-491. [2] 王琳源, 靳赢, 林晓萍. 适应性免疫应答在牙周炎发生中的作用 [J]. 中华口腔医学杂志, 2013, 48(2): 115-118. [3] Wang L, Wang J, Jin Y, et al. Oral administration of all-trans retinoic acid suppresses experimental periodontitis by modulating the Th17/Treg imbalance[J]. J Periodontol, 2014, 84(5): 740-750. [4] Hu Y, Dong C, Yue Y, et al. In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells [J]. Arch Virol, 2014, 159(9): 2411-2419. [5] Terayama H, Yoshimoto T, Hirai S, et al. Contribution of IL-12/IL-35 common subunit p35 to maintaining the testicular immune privilege [J]. PLoS One, 2014, 9(4): e96120. [6] Liu JQ, Liu Z, Zhang X, et al. Increase Th17 and regulatory T cell responses in EBV-induced gene3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis[J]. J Immunol, 2012, 188(7): 3099-3106. [7] Tirotta E, Duncker P, Oak J, et al. Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis [J]. J Neuroimmunol, 2013, 254(1-2): 110-116. [8] Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 + T cells regulates tissue inflammation by producing interleukin 17 [J]. Nat Immunol, 2005, 6(11): 1133-1141. [9] 孟焕新. 牙周病学[M]. 第3版. 北京: 人民卫生出版社, 2008: 118-124,191. [10] 吴赟, 陈凌, 魏斌, 等. 龈下及动脉粥样硬化斑块中牙周致病菌的同源性分析 [J]. 口腔医学研究, 2013, 29(6): 543-546. [11] Zhou X, Han J, Liu Z, et al. Effects of periodontal treatment on lung function and exacerbation frequency in patients with chronic obstructive pulmonary disease and chronic periodontitis: a 2-year pilot randomized controlled trial[J]. J Clin Periodontol,2014,41(6): 564-572. [12] Hern��ndez M1, Dutzan N, García-Sesnich J, et al. Host-pathogen interactions in progressive chronic periodontitis[J]. J Dent Res, 2011, 90(10): 1164-1170. [13] 王琳源, 靳赢, 林晓萍. CD4 + T细胞在不同菌株诱导小鼠牙周炎中的表达 [J]. 上海口腔医学, 2014, 23(1): 20-25. [14] Huang Y, Lin YZ, Shi Y, et al. IL-35: a potential target for the treatment of atherosclerosis[J]. Pharmazie, 2013, 68(10): 793-795. [15] Wang Y, Dong JB, Meng WY, et al. Effects of phased joint intervention on IL-35 and IL-17 expression levels in patients with portal hypertension [J]. Int J Mol Med, 2014, 33(5): 1131 -1139. [16] Pope RM, Shahrara S. Possible roles of IL-12-family cytokines in rheumatoid arthritis [J]. Nat Rev Rheumatol, 2013, 9(4): 252-256. [17] Kempe S, Heinz P, Kokai E, et al. Epstein-barr virus-induced gene-3 is expressed in human atheroma plaques [J]. Am J Pathol, 2009, 175(1): 440-447. [18] 台适, 周胜华, 刘启明, 等. 冠心病患者血浆白细胞介素35水平及临床意义的探讨[J]. 临床心血管病杂志, 2014, 30(1): 81-84. [19] Kochetkova I, Golden S, Holderness K, et al. IL-35 stimulation of CD39 + regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10 [J]. J Immunol, 2010, 184(12): 7144-7153. [20] Wirtz S, Billmeier U, Mchedlidze T, et al. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis [J]. Gastroenterology, 2011, 141(5):1875-1886. [21] Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases [J]. Nature, 2014, 507(7492): 366-370. [22] Kalburgi NB, Muley A, Shivaprasad BM, et al. Expression profile of IL-35 mRNA in gingiva of chronic periodontitis and aggressive periodontitis patients: a semiquantitative RT-PCR study [J]. Dis Markers, 2013, 35(6): 819-823. [23] Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population [J]. Nat Immunol, 2010, 11(12): 1093-1101. |